Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsmedical mutual - ohio medical drug Prior Auth upda…
    Ask Trek AI about this page
    Modifiedmedical mutual - ohioPolicy N/A

    Medical Drug Prior Authorization (Global PA) — Commercial & Medicare Advantage coverage criteria

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Medical Mutual's prior authorization requirements and contact/process details for medical-administered drugs (Commercial and Medicare Advantage), including specialty drugs and medications with safety or diversion concerns.

    Policy Summary
    Payermedical mutual - ohio
    PolicyMedical Drug Prior Authorization (Global PA) — Commercial & Medicare Advantage coverage criteria
    Policy CodePolicy N/A
    Change TypeNew prior authorization effective dates added
    Effective DateMay 15, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for listed medical-administered drugs for both Commercial and Medicare Advantage members before providing service.
    SourceLink
    POLICY UPDATE CHANGES

    New prior authorization requirements effective on various dates (examples: New PA requirement effective 1/1/26; 11/1/2025; 3/1/26; 5/1/26).

    Commercial & Medicare AdvantagePlans governed
    1-800-424-7698PA phone
    1/1/2025Medication sourcing start
    7/1/26New sourcing effective
    multipleEntries with new PA dates
    20+Codes listed (excerpt)

    Coverage Criteria and Product-Level Rules

    inv-01: General coverage criteria

    Prior authorization is required for listed drugs when used under the medical benefit; individual drug entries reference specific commercial and Medicare Advantage criteria codes or articles.

    Global PA requirement: Prior authorization must be obtained for drugs listed in this document for both Commercial and Medicare Advantage enrollees unless an individual drug entry specifies otherwise.

    See per‑drug criteria codes for clinical requirements (e.g., IC‑0598, IC‑0001, NCD references).

    inv-02: Drug coverage metadata

    Coverage and authorization are governed by the listed commercial criteria IDs and site-of-care indicators for each drug when present.

    Per-drug coverage metadata: Each drug entry includes: HCPCS/J-code, Brand Name, Generic Name, Classification, Commercial Criteria reference (e.g., 201528), Commercial Site of Care flag (✓ if subject), Medication Sourcing start flags (e.g., (A,C,S)), and Medicare Advantage references.

    Providers must consult the referenced commercial criteria document for detailed medical necessity requirements.

    inv-03: Prior Authorization (inpatient and outpatient)

    Coverage and authorization notes by product

    PA for inpatient and outpatient: Prior Authorization required for inpatient and outpatient for specified gene/cell therapies and selected high‑cost products (examples: Q2055 Abecma, Q2058 Aucatzyl, Q2042 Kymriah, J3399 Zolgensma, C9399/J3590 entries noted as requiring PA for inpatient and outpatient).

    See individual product entries for commercial criteria codes and Medicare NCD references.

    inv-04: Medicare Advantage step therapy / NCD notes

    Medicare Advantage step therapy and NCD references

    Medicare step therapy/NCD: Certain products reference Medicare Part B Step Therapy Policy 201936 or National Coverage Determinations (NCDs) (examples: J9272 Jemperli, bevacizumab/Avastin products and related biosimilars, colony stimulating factors).

    Follow the referenced Medicare Part B Step Therapy Policy 201936 or cited NCD when Medicare Advantage notes indicate it applies.

    inv-05: Operational controls

    Site-of-care and medication sourcing controls

    Site of Care designation: Some products are marked with a Commercial Subject to Site of Care flag (✓) indicating site restrictions apply for administration (examples: J3262/Actemra, J0801/Acthar, J1290/Kalbitor, multiple J3590/C9399 entries).

    When present, PA requests should identify and comply with the site‑of‑care designation.

    Medication sourcing requirement: Multiple products list medication sourcing start indicators effective starting 1/1/2025 or other specified dates and may show codes such as (A),(C),(S); some entries also list later sourcing effective dates (examples: new sourcing effective 4/1/26, 7/1/26).

    Providers must follow medication sourcing instructions (white‑bagging/ship‑to) per the product entry when placing orders.

    inv-06: Per-drug commercial criteria

    Coverage and PA applicability are determined per listed Commercial Criteria identifiers for each drug entry.

    Per-drug commercial criteria: Each listed HCPCS/label is governed by the referenced Commercial Criteria ID (for example, J9203 governed by IC‑0320; J2941 governed by 95015; many J3590/C9399 entries reference numeric commercial criteria). Providers must meet the specific Commercial Criteria referenced for approval.

    Reference the exact Commercial Criteria identifier shown in the product entry when submitting PA documentation.

    inv-07: Product-level coverage linkage

    Coverage entries list product-level commercial criteria IDs and site-of-care flags; decisions depend on matching the applicable commercial criteria referenced.

    Product coverage mapping: Coverage and prior authorization decisions require adherence to the listed Commercial Criteria ID (e.g., Praluent = 201528; Privigen/Asceniv/Asceniv‑class immune globulins = IC‑0071) and any Medicare Advantage notes (e.g., LCD or Article references).

    Include the Commercial Criteria ID on PA requests and supply supporting clinical documentation per that criteria.

    inv-08: Product-level coverage links

    Listed products are associated with internal commercial or Medicare Advantage criteria and may have site-of-care or sourcing rules

    Product entry: Each drug entry includes code, brand/generic name, classification, commercial criteria reference, site‑of‑care flag (✓ when present), medication sourcing start dates (e.g., 1/1/2025 or later), and short operational notes (e.g., new PA effective dates).

    For clinical medical‑necessity requirements, follow the referenced commercial or Medicare Advantage criteria document associated with the product.

    inv-09: Code-specific coverage rules

    Coverage/authorization stance is code-specific per listed commercial criteria identifiers or explicit notes

    Per-code rule: For each listed HCPCS/CPT code, follow the referenced Commercial Criteria identifier (for example, CDP‑0549 governs J1823 Uplizna; IC‑0014 governs bevacizumab/Avastin biosimilars) or the explicit note shown (e.g., 'No PA required', 'PA required for inpatient and outpatient', 'Subject to Site of Care = ✓').

    This section lists identifiers and operational flags; full clinical eligibility and required documentation are defined in the referenced criteria documents or Medicare references.

    When a product listed in this document is identified as self‑administered in the Medicare Advantage notes (for example, entries where the notes state "Drug is self‑administered and is not covered under Part B. Drug may be covered under Part D."), coverage and prior authorization must follow the applicable prescription drug (Medicare Part D) pathway rather than the medical benefit. Providers should contact the member's pharmacy benefit manager using the number on the member ID card to confirm Part D prior approval requirements and routing. Prior authorization is still required for outpatient administration when the drug is billed under the medical benefit unless an individual drug entry specifies otherwise.

    Bevacizumab products (Avastin and biosimilars) listed in this document require prior authorization when used for non‑ophthalmic indications only. Ophthalmic uses (e.g., intraocular/retinal injections) are explicitly excluded from the PA requirement — follow the per‑product entry and referenced Commercial or Medicare Advantage criteria for full details and applicable step therapy guidance.

    Example: Several J3590/C9399 entries (and other listed products such as Praluent, Cosentyx, and somatropin) include Medicare Advantage notes indicating the drug is self‑administered and not covered under Part B; may be covered under Part D. In those cases, providers should bill and seek prior authorization under the pharmacy benefit (Part D) per the member's PBM requirements rather than the medical benefit.

    Examples of self‑administered biologics and other products that are annotated as not covered under Part B and possibly covered under Part D include multiple brands shown under J3590 / C9399 mappings (e.g., Cosentyx SC, Kevzara, Skyrizi SC, and other J3590/C9399 entries). For such entries the Medicare Advantage note indicates the pharmacy benefit should be consulted for coverage and prior authorization.

    Somatropin products (example: J2941 entries such as Zomacton) are flagged in Medicare Advantage notes as self‑administered and not covered under Part B; may be covered under Part D. When somatropin is self‑administered, providers should confirm benefit routing and obtain any required Part D authorizations through the PBM; if administered and billed under the medical benefit, follow the listed Commercial Criteria (e.g., 95015) and PA requirements.

    Billing note: when a drug is identified as self‑administered and may be covered under Part D, do not submit medical benefit claims under Medicare Part B for that product; instead, confirm Part D coverage with the member's PBM and follow the PBM's prior authorization process. If the drug is being provided under the medical benefit (e.g., administered in a facility and billed to the plan), obtain the medical PA per the Commercial/Medicare Advantage criteria listed in this document.

    Reminder: Avastin (bevacizumab) and bevacizumab biosimilars require prior authorization for non‑ophthalmic indications only. Ophthalmic uses are excluded from the PA requirement; follow the specific commercial criteria and Medicare Advantage notes for step therapy references and any effective dates that may apply.

    As noted elsewhere in the document, prior authorization is required for bevacizumab products (Avastin) when used for non‑ophthalmic indications only. Providers should reference the listed Commercial Criteria and Medicare Advantage guidance for any step therapy or site‑of‑care requirements associated with these codes.

    Additional reference: bevacizumab entries across multiple code mappings repeat that Avastin and its biosimilars require PA for non‑ophthalmic indications only. Ensure PA requests reference the correct HCPCS/Q‑code and the associated commercial/MA criteria shown in the product entry.

    Codes, Systems, and Medication Sourcing Dates

    Listed HCPCS/CPT codes and descriptionsHCPCS
    Q2055Abecma (idecabtagene vicleucel) — Oncology; Commercial Criteria = IC-0598, IC-0654-(E); Medicare Advantage Criteria = NCD: 110.24
    J9264Abraxane (paclitaxel protein bound particles) — Oncology; Commercial Criteria = IC-0001, IC-0360-(E)
    Q5145Abrilada (adalimumab-afzb) — Inflammatory conditions; Commercial Criteria = 200806
    J3262Actemra IV (tocilizumab) — Inflammatory conditions; Commercial Criteria = IC-0002
    J3590Actemra SC / multiple other products (tocilizumab and others) — various classifications; see individual entries for criteria codes
    J0801Acthar Gel (corticotropin) — Adrenocorticotropin stimulating hormone; Commercial Criteria = 201010-MRx
    J0791Adakveo (crizanlizumab-tmca) — Rare disease; Commercial Criteria = 202003
    J9029Adstiladrin (nadofaragene firadenovec-vncg) — Oncology; Commercial Criteria = IC-0691, IC-0745-(E)
    J7171Adzynma (ADAMTS13, recombinant-krhn) — Rare disease; Commercial Criteria = IC-0736
    Q5150Ahzantive (aflibercept-mrbb) — Ophthalmic; Commercial Criteria = 201513-EY
    1–10 of 27
    1/3
    Sample listed HCPCS/J-codes (partial)HCPCS
    J2277Aralast NP (alpha-1-proteinase inhibitor)
    J0256alpha-1-proteinase inhibitor (Aralast NP)
    J0881darbepoetin alfa (Aranesp)
    J2793rilonacept (Arcalyst)
    J9261nelarabine (Arranon)
    Continued HCPCS/J/Q/A codes from excerpt (partial)HCPCS
    J1554intravenous immune globulin (Asceniv)
    J9118calaspargase pegol-mknl (Asparlas)
    Q2058Obecabtagene autoleucel (Aucatzyl)
    Q5161denosumab-kyqq (Aukelso)
    J9035bevacizumab (Avastin)
    J3590tividenofusp alfa-eknm (Avlayah) / other J3590 entries
    J3145Testosterone undecanoate (Aveed)
    J9184gemcitabine hydrochloride (Avgemsi)
    J1826interferon beta-1a (Avonex)
    Q5121infliximab-axxq (Avsola)
    1–10 of 19
    1/2
    Mixed HCPCS/J and category codes (partial)mixed
    J3247listed with subject to site of care and medication sourcing notes
    C9399used with brand/generic identifiers (e.g., Cosentyx SC / secukinumab)
    J3590generic placeholder used with multiple brand/generic entries (e.g., dupilumab)
    Selected individual HCPCS/Q/J codes from excerptHCPCS
    Q5143Cyltezo (adalimumab - adbm)
    J9308Cyramza (ramucirumab)
    Q5108Fulphila (pegfilgrastim-jmdb)
    Listed HCPCS codes (sample)HCPCS
    J1744Firazyr; icatibant; Hereditary angioedema
    Listed HCPCS codes (sample)HCPCS
    J9331Fyarro; sirolimus albumin-bound nanoparticles; Oncology
    Listed HCPCS codes (sample)HCPCS
    J2941Genotropin / Humatrope; somatropin; Growth hormone
    Listed HCPCS codes (sample)HCPCS
    J0599Haegarda; c-1 esterase inhibitor (human); Hereditary angioedema
    Listed HCPCS/J-codes and descriptionsHCPCS
    C9309listed with Commercial Criteria = 231205; Classification = CNS: Rare Disease
    J9207Ixempra / ixabepilone — Oncology
    J2782Izervay / avacincaptad pegol — Ophthalmic injections
    J9281Jelmyto / mitomycin — Oncology
    J9272Jemperli / dostarlimab-gxly — Oncology
    J9043Jevtana / cabazitaxel — Oncology
    Q5160Jobevne / bevacizumab-nwgd — Inflammatory conditions
    J3590Used for multiple brands (e.g., denosumab-desu, Kesimpta, Kevzara, anakinra, and many C9399 cross-listings)
    C9399Used with J3590 for multiple gene/rare-disease products (e.g., Kebilidi, Kresladi)
    J2840Kanuma / sebelipase alfa — Enzyme replacement therapy
    1–10 of 43
    1/5
    Covered HCPCS codes (sample from excerpt)HCPCSCovered
    J9203Mylotarg (gemtuzumab ozogamicin) — Oncology; Commercial Criteria = IC-0320, IC-0491-(E)
    Growth hormone codesHCPCSCovered
    J2941Norditropin / Omnitrope / Nutropin AQ (somatropin) — Growth hormone; Commercial Criteria 95015
    Immune globulinHCPCSCovered
    J1568Octagam (intravenous immune globulin) — IC-0071
    OncologyHCPCSCovered
    J9299Opdivo IV (nivolumab) — Oncology; Commercial Criteria IC-0226, IC-0541-(E)
    Additional biologics and injectablesHCPCSCovered
    J1459Privigen (intravenous immune globulin) — IC-0071
    J0885Procrit (epoetin alfa) — Erythropoiesis stimulating agents; Commercial Criteria 201832
    Listed HCPCS codes in segmentHCPCS
    J3590Praluent / alirocumab referenced under J3590,C9399 in this section
    C9399Used alongside J3590 for multiple self‑administered biologics (e.g., Praluent, Repatha)
    J1459Privigen (intravenous immune globulin)
    J1459intravenous immune globulin (Privigen) -- classification and criteria referenced
    Additional HCPCS/G-codesHCPCS | G-code
    J2326Spinraza (nusinersen)
    J0013Spravato (esketamine) and G2082, G2083 variants
    Selected HCPCS/J-codes (partial list)HCPCS
    J1299Soliris; eculizumab; Rare disease; Commercial Criteria = 201421
    J1930Somatuline Depot; lanreotide; Oncology, Endocrine; Commercial Criteria = IC-0115
    J1747Spevigo IV/SC; spesolimab; Inflammatory conditions; Commercial Criteria = IC-P0674 / 250402
    Covered HCPCS/J and miscellaneous codes listed in this partHCPCSCovered
    J2326Spinraza; nusinersen; CNS: Rare diseases; Commercial Criteria = 201705
    J0013Spravato; esketamine; Psychotherapeutic; Commercial Criteria = 201911 - MRx
    J3590 C9399Starjemza; ustekinumab-hmny; Inflammatory conditions; Commercial Criteria = 201012-2 / 201012
    J3358Stelara IV; ustekinumab; Inflammatory conditions; Commercial Criteria = 201012-2
    J3357Stelara SC; ustekinumab; Inflammatory conditions; Commercial Criteria = 201012
    Q5099Steqeyma IV/SC; ustekinumab-stba; Inflammatory conditions; Commercial Criteria = 201012-2 / 201012
    Q5127Stimufend; pegfilgrastim-fpgk; Colony stimulating factors; Commercial Criteria = 201827
    J7321Supartz; hyaluronan derivative; Viscosupplementation; Commercial Criteria = 99002
    J2779Susvimo; ranibizumab; Ophthalmic injections; Commercial Criteria = IC-0634
    J2781Syfovre; pegcetacoplan; Ophthalmic injections; Commercial Criteria = IC-0697
    1–10 of 97
    1/10
    Covered HCPCS (entries listed)HCPCS
    J1823Uplizna (inebilizumab-cdon) — Hematology: NMOSD; Commercial Criteria = CDP-0549
    Covered HCPCS (entries listed)HCPCS
    J9217Vabrinty (leuprolide acetate depot) — Oncology; Commercial Criteria = 221201
    Listed HCPCS/Codes and descriptionsmixed
    J2777Vabysmo (faricimab-svoa) — Ophthalmic injections; Criteria = IC-0659
    J9303Vectibix (panitumumab) — Oncology; Criteria = IC-0136, IC-0389-(E)
    Q5129Vegzelma (bevacizumab-adcd) — Oncology; Criteria = IC-0014, MMO-0450-(E)
    J1325Veletri (epoprostenol) — Pulmonary arterial; Criteria = 201806; Subject to Site of Care = ✓
    Q4074Ventavis (iloprost) — Pulmonary arterial hypertension; Criteria = 201807; Subject to Site of Care = ✓
    J9376Veopoz (pozelimab-bbfg) — Rare disease; Criteria = IC-0727
    J1427Viltepso (viltolarsen) — Rare disease; Criteria = IC-0562; Subject to Site of Care = ✓
    J1322Vimizim (elosulfase alfa) — Enzyme replacement therapy; Criteria = IC-0190; Subject to Site of Care = ✓
    J7321Visco-3 (hyaluronan or derivative) — Viscosupplementation; Criteria = 99002
    J3396Visudyne (verteporfin) — Ophthalmic injections; Criteria = IC-0181
    1–10 of 47
    1/5
    inv-41: Medication Sourcing start date — common start 1/1/2025 and other specific dates
    Common medication sourcing start dateMany products: Medication Sourcing start date = 1/1/2025
    Examples of later sourcing start datesEntries note additional new sourcing effective dates (examples: 2/1/26, 5/1/26)
    Products with (A,C,S) sourcing codesSeveral high-cost and rare-disease products list sourcing categories (A,C,S) effective 1/1/2025
    Somatropin / growth hormone noteSomatropin entries flagged with Medication Sourcing starting 1/1/2025 (see J2941/J2941-related entries)
    Avastin / bevacizumab noteSome bevacizumab biosimilars list sourcing entries with 1/1/2025 noted (see Q5129 and related Avastin entries)
    inv-42: Medication sourcing effective dates — examples include 1/1/2025, 4/1/2026, 7/1/2026
    Examples of new sourcing effective 4/1/2026Q5099 / Q5138 / Q5130 and other ustekinumab-related or similar entries note new medication sourcing requirements effective 4/1/26
    Examples of new sourcing effective 7/1/2026Multiple entries (e.g., J1930, Q5099 variants, Q5154) reference new medication sourcing effective 7/1/26
    Common baseline dateMany entries still indicate Medication Sourcing starting 1/1/2025
    Other interim effective datesDocument includes other effective dates such as 2/1/26 and 5/1/26 for select products
    inv-43: Medication sourcing effective dates — assorted dates starting 1/1/2025 and later
    Assorted effective dates starting 1/1/2025Document lists numerous entries with Medication Sourcing starting 1/1/2025 and additional effective dates thereafter (examples: 11/1/25, 2/1/26, 4/1/26, 5/1/26, 7/1/26)
    New PA timing associated with sourcingSome products list new PA requirements tied to sourcing effective dates (e.g., Leqembi Leqembi Iqlik new PA 11/1/2025)
    Entries with 7/1/26 sourcingSeveral J3590/C9399 and Q-codes note new medication sourcing requirement effective 7/1/26
    Entries with 4/1/26 sourcingSelected products (e.g., Q5099 variants, Q5138) reference new medication sourcing effective 4/1/26

    Prior Authorization Process, Submission, and Operational Guidance

    Prior Authorization

    Prior Authorization Required

    Prior Authorization Required. Medical Mutual requires prior authorization (PA) for the listed medical drugs for Commercial and Medicare Advantage members. Failure to obtain PA prior to administration may result in denial of coverage.

    • Applies to all new specialty drugs and new drugs with significant safety, clinical, or diversion concerns.
    • PA requirement applies to both inpatient and outpatient settings where noted in the drug listing.
    • For Medicare Advantage, Medical Mutual follows CMS guidance and applicable NCDs/LCDs; Medicare coverage is limited to clinically proven items and services.
    Documentation Required

    How to Submit Prior Authorization

    How to submit prior authorization requests. Providers should submit PA requests to Medical Drug Management using the contact channels below; use the Prior Approval Form when available.

    • Medicare Part B / Medicare Advantage requests: Phone 1-800-424-7698; Fax 1-888-656-1948; Web: www.gatewaypa.com
    • Commercial and Exchange requests: Phone 1-800-424-7698; Fax 1-888-656-1948; Web: www.gatewaypa.com (handled by Prime Therapeutics for Commercial)
    Prior Authorization

    Icatibant (Firazyr) PA and Sourcing

    Icatibant (Firazyr) (J1744) requires prior authorization and is subject to medication sourcing and site-of-care flags for Commercial plans. Note Medicare Advantage: this product is typically self-administered and may be Part D rather than Part B.

    • Code: J1744 — Commercial Criteria: 201509-MRx
    • Commercial Subject to Site of Care: ✓; Medication Sourcing Starting 1/1/2025 = (A,C)
    • New medication sourcing requirement effective 7/1/2026
    • Medicare Advantage Criteria: Article A52527 — Medicare notes: drug is self-administered and not covered under Part B; may be covered under Part D
    Prior Authorization

    Fyarro (J9331) PA

    Fyarro (J9331) requires prior authorization per the listed commercial criteria (IC-0647) and Medicare Advantage criteria. Confirm PA prior to administration.

    • Code: J9331 — sirolimus albumin-bound nanoparticles
    • Commercial Criteria: IC-0647, IC-0681-(E); Medicare Advantage Criteria: IC-0647
    • Medication sourcing and site-of-care flags as listed in the drug-specific row should be followed
    Prior Authorization

    Somatropin (J2941) PA and Sourcing

    Somatropin (Zomacton, J2941) requires prior authorization under Commercial Criteria 95015 and has site-of-care and medication sourcing flags; for Medicare Advantage the product is typically self-administered and may be covered under Part D.

    • Code: J2941 — Commercial Criteria: 95015
    • Commercial Subject to Site of Care: ✓; Medication Sourcing Starting 1/1/2025 = (A,C)
    • New medication sourcing requirement effective 7/1/26
    • Medicare Advantage Criteria: Article A52527 — Medicare notes: drug is self-administered and not covered under Part B; may be covered under Part D
    Documentation Required

    Medication Sourcing and PA Timing

    Medication sourcing and PA timing. Providers ordering drugs that are subject to the Medication Sourcing Program should follow the processing recommendations to avoid shipment delays when white-bagging to hospital outpatient infusion departments.

    • Medication Sourcing Program effective 1/1/2025 — follow specialty pharmacy submission guidance (clinical documentation, signed prescription, member demographics).
    • On referral forms, specify medical benefit billing, indicate 'Drug is to be sourced/white bagged', include ship-to location and required delivery date.
    • Members should be informed the specialty pharmacy will contact them; timely member response prevents shipment delays.
    • Some products have future sourcing effective dates (examples in drug rows: new sourcing requirements effective 4/1/26, 7/1/26, etc.).
    Documentation Required

    Vyvgart Hytrulo Sourcing

    Vyvgart Hytrulo (J9334) medication sourcing change. Vyvgart Hytrulo is subject to a new medication sourcing requirement — providers must account for the sourcing requirement when submitting PA and scheduling therapy.

    • Code: J9334 — Commercial Criteria: CDP-0712; Commercial Subject to Site of Care: ✓
    • Commercial Subject to Medication Sourcing Starting 1/1/2025 = (A,C,S)
    • New medication sourcing requirement effective 4/1/2026 — ensure PA requests include sourcing details and ship-to location
    Prior Authorization

    Oncology / Avastin Prior Authorization

    Oncology agents and Avastin (bevacizumab) PA. Avastin and bevacizumab biosimilars require prior authorization for non-ophthalmic indications only. Many oncology agents also require PA for inpatient and outpatient use — verify drug-specific rows for PA, criteria, and step-therapy cross-references.

    • Avastin (bevacizumab) and bevacizumab products (J9035, Q5126, Q5107, Q5160, J9999, Q5118, Q5129, Q5118, etc.): PA required for non-ophthalmic indications only; ophthalmic injections are treated separately.
    • Oncology CAR-T and other cell/gene therapies (e.g., Abecma Q2055, Carvykti Q2056, Kymriah Q2042, Yescarta Q2041, Tecartus Q2053, etc.): Prior Authorization required for both inpatient and outpatient and may reference NCD 110.24 for Medicare Advantage.
    • Refer to each drug's Commercial Criteria ID and Medicare Advantage Criteria entry for specific coverage rules and site-of-care or sourcing notes.
    Step Therapy

    Reference Commercial Criteria & Medicare Part B Step Therapy

    Reference commercial criteria and Medicare Part B Step Therapy. PA requests should reference the applicable Commercial Criteria ID listed for each HCPCS/CPT/J-code product. Where the Medicare Advantage Notes reference Medicare Part B Step Therapy Policy 201936, follow the step therapy requirements for Medicare Advantage members.

    • Always include the Commercial Criteria identifier (e.g., IC-0598, IC-0647, CDP-0649, 95015, etc.) on PA requests to expedite review.
    • Medicare Part B Step Therapy Policy 201936 is cross-referenced for multiple agents — when noted in the Medicare Advantage Notes, follow that Step Therapy policy for MA members.
    • New Medicare Advantage step therapy requirements are effective for certain agents on 5/1/2026 (see drug-specific entries).
    • If a drug is noted as self-administered in Medicare notes (Article A52527), it may not be a Part B benefit and could instead be Part D — confirm benefit pathway to avoid billing denials.

    Site-of-Care Flags and Administration Location Guidance

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Medicare Part B Step Therapy Cross-References

    ReferenceSummary
    Medicare Part B Step Therapy Policy 201936Some drug entries in this document reference Medicare Part B Step Therapy Policy 201936; providers must follow the step therapy requirements in that policy where indicated in per‑product Medicare Advantage notes.
    See per‑product Medicare Advantage notesMultiple entries include a Medicare Advantage note directing: 'See Medicare Part B Step Therapy Policy 201936.' When present, Step Therapy Policy 201936 governs step therapy requirements for Medicare Advantage members.
    ReferenceApplicability
    Medicare Part B Step Therapy Policy 201936Referenced repeatedly in Medicare Advantage criteria notes; follow Policy 201936 for step therapy requirements affecting Medicare Advantage enrollees.
    Examples of affected agentsExamples in the document referencing Policy 201936 include bevacizumab products (Avastin and biosimilars), selected colony stimulating factors, immune globulins, and multiple oncology agents; see individual code entries for specifics.
    ReferenceEffective date / Note
    Medicare Part B Step Therapy Policy 201936Some Medicare Advantage notes state a new Step Therapy requirement becomes effective 5/1/2026; when that date is shown in an entry, Step Therapy Policy 201936 requirements apply beginning 5/1/2026 for those agents.
    Document examplesMultiple oncology and biologic entries include the note: 'New Medicare Advantage Step Therapy requirement effective 5/1/2026.' Providers should observe those effective dates in Medicare Advantage cases.
    ReferenceExample products
    J9272 (Jemperli); bevacizumab products (Avastin and biosimilars); colony stimulating factorsMedicare Advantage notes on these products reference See Medicare Part B Step Therapy Policy 201936; follow that policy for step therapy requirements for these products as indicated.
    Selected oncology agents (e.g., J9022 Tecentriq, J9299 Opdivo, J9380 Tecvayli)These entries include Medicare Advantage references to Policy 201936 and some indicate new Step Therapy effective dates; follow Policy 201936 per the product note.
    ReferenceInstruction
    See Medicare Part B Step Therapy Policy 201936Where a product's Medicare Advantage notes state 'See Medicare Part B Step Therapy Policy 201936,' providers must follow that step therapy policy for Medicare Advantage members; consult the referenced policy for detailed step requirements.
    Per‑product cross‑referenceSeveral immune globulin and biologic entries include this cross‑reference; the plan's Medicare Advantage step therapy handling is governed by Policy 201936 for those products.
    ReferenceOccurrences
    Multiple product entriesThe document contains multiple instances where product Medicare Advantage notes state 'See Medicare Part B Step Therapy Policy 201936.' These references appear across oncology, biologic, and immune globulin entries—follow Policy 201936 where cited.
    Examples include:Entries for J9321 (Epkinly), J9145 (Darzalex), J9272 (Jemperli), J9022 (Tecentriq), and various bevacizumab biosimilars include the Step Therapy 201936 reference.
    ReferenceNotes on effective dates and products
    Medicare Part B Step Therapy Policy 201936 referencesDocument entries note new Medicare Advantage Step Therapy requirements becoming effective on various dates (notably 5/1/2026 for many entries); providers should check the per‑product Medicare Advantage note for the effective date and follow Policy 201936 accordingly.
    Product examples with effective datesExamples include multiple oncology agents and select biologics where the Medicare Advantage note includes 'New Medicare Advantage Step Therapy requirement effective 5/1/2026.'
    ReferenceGuidance
    Follow Medicare Part B Step Therapy Policy 201936 when citedAcross the document, Medicare Advantage criteria or notes that reference Policy 201936 indicate that step therapy requirements in that policy govern Medicare Advantage members for the named products; providers must follow those step therapy requirements and the specified effective dates where present.
    Provider actionWhen a product entry includes a Medicare Advantage note citing Step Therapy Policy 201936 (and any effective date), include adherence to that policy in the prior authorization submission for Medicare Advantage members.

    Policy Background and Scope

    Background: This document enumerates medical‑administered drugs that require prior authorization to ensure safe and effective use. It applies to drugs administered under the medical benefit for both Commercial and Medicare Advantage members and includes per‑product Commercial Criteria references, site‑of‑care flags, and medication sourcing start dates (many effective 1/1/2025 or later). Where Medicare Advantage notes indicate a product is self‑administered and not covered under Part B, the document also directs providers to the member's PBM for Part D prior authorization requirements.

    Key Definitions and Operational Terms

    inv-90: Investigational / Experimental definition
    Investigational / Experimental definitionServices, procedures, therapies, devices and supplies not approved by governing bodies or that do not demonstrate comparable or superior outcomes to current practice standards as evidenced by peer-reviewed literature.
    ScopeApplies to services lacking regulatory approval or sufficient peer-reviewed evidence to show effectiveness over current standards
    Use in policyInvestigational/Experimental designation excludes coverage unless otherwise specified in product-specific criteria
    inv-91: Medication Sourcing — operational designation and effective dates
    Operational designation'Commercial Subject to Medication Sourcing Starting' denotes operational sourcing requirements for listed products with start dates (commonly 1/1/2025) and product-specific sourcing codes (A,C,S).
    Tied to PA and shippingMedication sourcing entries often accompany PA requirements and guidance for hospital outpatient infusion sourcing/white-bagging
    Examples in documentEntries include specific product-level sourcing notes (e.g., J9203, J3590/C9399 products, J1930) and later effective sourcing dates for some items
    inv-92: Site of Care — flag meaning (✓ indicates subject to site-of-care)
    Site of Care flag meaningA check mark (✓) indicates the product is subject to site-of-care designation and related authorization/site restrictions (e.g., infusion center, hospital outpatient, office, or home per product).
    Action for providersWhen ✓ is present, providers must specify and follow the site-of-care requirements on PA requests
    ExamplesProducts flagged include J1290, J2507, J1458, J3590/C9399 entries, and others listed across the document
    inv-93: Commercial Criteria — short definition and usage
    Commercial Criteria definitionInternal policy or criteria identifiers referenced for each drug (e.g., IC-0071, 201528) that define coverage and medical necessity requirements used to adjudicate prior authorization requests.
    How usedProviders must reference the Commercial Criteria ID listed for the HCPCS/J-code when submitting PA documentation
    Where listedCommercial Criteria IDs appear in each product entry alongside code, brand/generic name, site-of-care and sourcing flags
    inv-94: Subject to Site of Care — indicates payer applies site-of-care restrictions
    Subject to Site of Care meaningIndicates the payer applies site-of-care restrictions for administration; when present a check mark (✓) signals PA may require the site to be specified and approved.
    Implication for schedulingPA approvals may be contingent on approved site-of-care (e.g., infusion center vs office vs home)
    ExamplesDocument lists many products with 'Subject to Site of Care = ✓' such as J1325, J1458, J3590/C9399 entries
    inv-95: Medicare Part D vs Part B — notes when drug is self-administered and not covered under Part B; may be Part D
    Medicare Part D vs Part B noteEntries note when a drug is self-administered and 'not covered under Part B; may be covered under Part D,' affecting billing and benefit routing.
    Provider actionWhen Medicare Advantage notes indicate Part D coverage possible, verify benefit pathway and follow pharmacy benefit manager requirements if under Part D
    Examples in documentPraluent (J3590), Stelara SC/J3357 entries and other self-administered biologics include this Part B vs Part D language
    inv-96: Commercial Subject to Medication Sourcing Starting — indicates dates and source categories when sourcing rules apply
    Commercial Subject to Medication Sourcing StartingDenotes the date and sourcing categories (e.g., A, C, S) when medication sourcing rules apply for the product; common start = 1/1/2025 with product-specific later effective dates noted (examples: 4/1/26, 7/1/26)
    Sourcing category codesEntries list sourcing categories in parentheses (A,C,S) to indicate sourcing source requirements per product
    Effect on authorizationNew sourcing requirements may affect PA and authorization if sourcing/compliance is not met on or after the effective date
    inv-97: Commercial Criteria — internal policy or criteria reference code definition
    Commercial Criteria (internal code) definitionAn internal policy/criteria reference code (e.g., IC-0115, 201421, CDP-0549) that prescribes medical necessity, site-of-care, and documentation requirements for the listed product.
    Requirement for PAPA determinations rely on meeting the requirements specified in the referenced Commercial Criteria ID
    Reference on requestsProviders should reference the Commercial Criteria ID from the product entry when submitting prior authorization documentation

    Policy Updates and Material Changes

    2026-05-15document_effective_dateLatest

    Policy effective date published as 2026-05-15; document lists multiple new PA and medication sourcing effective dates across 2025–2026.

    2026-05-01medicare_advantage_step_therapy_addition

    New Medicare Advantage step therapy requirement referenced (see Medicare Part B Step Therapy Policy 201936) effective 2026-05-01 for select agents.

    2026-04-01medication_sourcing_requirement

    New medication sourcing requirement effective 2026-04-01 for selected products (example: Q5138 shows new sourcing requirement effective 4/1/26).

    2026-02-01new_prior_authorization_requirement

    New prior authorization requirement effective 2026-02-01 for select J3490/C9399 entries (example: Yartemlea noted with new PA requirement effective 2/1/26).

    2025-11-01new_prior_authorization_requirement

    New prior authorization requirement effective 2025-11-01 for specified J3490/C9399 product(s) referenced elsewhere in the document.

    2025-07-01medication_sourcing_requirement

    New medication sourcing requirements effective 2025-07-01 for certain products (examples: multiple entries note sourcing effective 7/1/26 in the broader series; document lists 7/1/26 as a sourcing date category).

    2025-01-01medication_sourcing_program_start

    Medication sourcing program start date for many products (Commercial Subject to Medication Sourcing starting 1/1/2025).

    Policy Summary
    Payermedical mutual - ohio
    PolicyMedical Drug Prior Authorization (Global PA) — Commercial & Medicare Advantage coverage criteria
    Policy CodePolicy N/A
    Change TypeNew prior authorization effective dates added
    Effective DateMay 15, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for listed medical-administered drugs for both Commercial and Medicare Advantage members before providing service.
    SourceLink
    On This Page
    Coverage Criteria and Product-Level RulesCodes, Systems, and Medication Sourcing DatesPrior Authorization Process, Submission, and Operational GuidanceSite-of-Care Flags and Administration Location GuidanceMedicare Part B Step Therapy Cross-ReferencesPolicy Background and ScopeKey Definitions and Operational TermsPolicy Updates and Material Changes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.